Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:veterinary_medicine
|
| gptkbp:activeIngredient |
mirtazapine
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
cats |
| gptkbp:ATCCode |
QNO6AX11
|
| gptkbp:contraindication |
hypersensitivity to mirtazapine
|
| gptkbp:form |
gptkb:hospital
|
| gptkbp:manufacturer |
Dechra Pharmaceuticals
|
| gptkbp:mechanismOfAction |
appetite stimulant
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
topical
|
| gptkbp:sideEffect |
behavioral changes
vomiting application site reactions increased vocalization |
| gptkbp:usedFor |
management of weight loss in cats
|
| gptkbp:bfsParent |
gptkb:Kindred_Biosciences
|
| gptkbp:bfsLayer |
9
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mirataz
|